


AMENDMENTS TO THE CLAIMS

Claims 1-48 . (Canceled)

49. (Currently Amended) A method of treating macular degeneration, which comprises administering to a patient having macular degeneration ~~in need thereof~~ a therapeutically effective amount of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione ~~1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline~~ having the formula:



or stereoisomer thereof or a pharmaceutically acceptable salt, ~~solvate or stereoisomer~~ thereof.

50-56. (Canceled)

57. (Previously Presented) The method of claim 49 wherein the method comprises administering a therapeutically effective amount of a second active agent.

58. (Currently Amended) The method of claim 57 wherein the second active agent is a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, ~~a xanthine derivative~~, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound.

59. (Currently Amended) The method of claim 57 wherein the second active agent is thalidomide, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2 α or pentoxifylline, or a pharmaceutically acceptable salt, ~~solvate, or stereoisomer~~ stereoisomer thereof.

60. (Currently Amended) The method of claim 58 wherein the second active agent ~~antiangiogenesis compound~~ is thalidomide.

61. (Previously Presented) The method of claim 49 wherein the macular degeneration is wet macular degeneration, dry macular degeneration, age-related macular degeneration, age-related maculopathy, choroidal neovascularisation, retinal pigment epithelium detachment, atrophy of retinal pigment epithelium, Best's disease, vitelliform, Stargardt's disease, juvenile macular dystrophy, fundus flavimaculatus, Behr's disease, Sorsby's disease, Doyne's disease, honeycomb dystrophy, or macular damaging condition.

62. (Previously Presented) The method of claim 49 wherein the compound is stereomerically pure.

63. (Previously Presented) The method of claim 49 wherein the compound is administered before, during or after surgical intervention directed at reducing or avoiding a symptom of macular degeneration in a patient.

64. (Previously Presented) The method of claim 63 wherein the surgical intervention is light therapy, laser therapy, retinal pigment epithelium transplantation, or foveal translocation.